Diabetes, Obesity and Metabolism

Cover image for Vol. 18 Issue 6

Accepted Articles (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)

Edited By: R. Donnelly and A. Garber

Impact Factor: 6.36

ISI Journal Citation Reports © Ranking: 2014: 14/128 (Endocrinology & Metabolism)

Online ISSN: 1463-1326


  1. 1 - 17

    1. Randomized, Double-Blind Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination With Prandial Insulin Lispro, in Patients with Type 2 Diabetes: IMAGINE 4

      Thomas Blevins, Thomas R. Pieber, Gildred Colón Vega, Shuyu Zhang, Edward J. Bastyr III, Annette M. Chang and on behalf of the IMAGINE 4 Investigators

      Accepted manuscript online: 28 MAY 2016 05:05AM EST | DOI: 10.1111/dom.12696


    1. Add-on treatment with intermediate-acting insulin versus sliding scale insulin for patients with type 2 diabetes or insulin resistance during cyclic glucocorticoid-containing antineoplastic chemotherapy – a randomized cross-over study

      Maaike C. Gerards, Josanne de Maar, Tessa G. Steenbruggen, Joost B. L. Hoekstra, Titia M. Vriesendorp and Victor E.A. Gerdes

      Accepted manuscript online: 18 MAY 2016 11:07AM EST | DOI: 10.1111/dom.12694


    1. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalisation and mortality records

      Salwa S Zghebi, Douglas T Steinke, Martin K Rutter, Richard A Emsley and Darren M Ashcroft

      Accepted manuscript online: 13 MAY 2016 11:50PM EST | DOI: 10.1111/dom.12692


    1. Effects of Lorcaserin on Fat and Lean Mass Loss in Obese and Overweight Patients Without and With Type 2 Diabetes Mellitus: the BLOSSOM and BLOOM-DM Studies

      Caroline Apovian, Kenya Palmer, Randi Fain, Carlos Perdomo and Domenica Rubino

      Accepted manuscript online: 13 MAY 2016 03:50AM EST | DOI: 10.1111/dom.12690


    1. Glucodynamics of Long-Acting Basal Insulin Peglispro (BIL) Compared With Insulin Glargine at Steady State in Subjects with Type 1 Diabetes: substudy of a randomized crossover trial

      Linda A. Morrow, Marcus Hompesch, Scott J. Jacober, Siak Leng Choi, Yongming Qu and Vikram P. Sinha

      Accepted manuscript online: 12 MAY 2016 04:45AM EST | DOI: 10.1111/dom.12691

    2. Treatment Intensification for Patients with Type 2 Diabetes and Poor Glycemic Control

      Alex Z. Fu and John Sheehan

      Accepted manuscript online: 10 MAY 2016 04:45AM EST | DOI: 10.1111/dom.12683

    3. Risk prediction of major complications in persons with diabetes: The Atherosclerosis Risk in Communities Study

      Christina M. Parrinello, Kunihiro Matsushita, Mark Woodward, Lynne E. Wagenknecht, Josef Coresh and Elizabeth Selvin

      Accepted manuscript online: 10 MAY 2016 04:36AM EST | DOI: 10.1111/dom.12686


    1. You have full text access to this OnlineOpen article
      Extracellular microRNAs and endothelial hyperglycemic memory: a therapeutic opportunity?

      Francesco Prattichizzo, Angelica Giuliani, Valeria De Nigris, Gemma Pujadas, Artan Ceka, Lucia La Sala, Stefano Genovese, Roberto Testa, Antonio Domenico Procopio, Fabiola Olivieri and Antonio Ceriello

      Accepted manuscript online: 10 MAY 2016 04:36AM EST | DOI: 10.1111/dom.12688


    1. You have full text access to this OnlineOpen article
      Comparable efficacy and safety of once weekly dulaglutide in patients with type 2 diabetes ≥65 and <65 years of age

      Malaz A. Boustani, Isaiah Pittman IV, Maria Yu, Vivian T. Thieu, Oralee J. Varnado and Rattan Juneja

      Accepted manuscript online: 10 MAY 2016 04:25AM EST | DOI: 10.1111/dom.12687

    2. Rates and predictors of hypoglycaemia in 27,585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study

      Kamlesh Khunti, Saud Alsifri, Ronnie Aronson, Maja Cigrovski Berković, Catherine Enters-Weijnen, Tom Forsén, Gagik Galstyan, Petronella Geelhoed-Duijvestijn, Margalit Goldfracht, Helge Gydesen, Rahul Kapur, Nebojsa Lalic, Bernhard Ludvik, Erik Moberg, Ulrik Pedersen-Bjergaard, Ambady Ramachandran and on behalf of the HAT Investigator Group.

      Accepted manuscript online: 10 MAY 2016 04:25AM EST | DOI: 10.1111/dom.12689

    3. You have full text access to this OnlineOpen article
      Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin

      Helena W. Rodbard, Jochen Seufert, Naresh Aggarwal, Anjun Cao, Albert Fung, Michael Pfeifer and Maria Alba

      Accepted manuscript online: 10 MAY 2016 03:10AM EST | DOI: 10.1111/dom.12684


    1. Diabetes and obesity treatment based on dual incretin receptor activation - “twincretins”

      Marius A. Skow, Natasha C. Bergmann and Filip K. Knop

      Accepted manuscript online: 10 MAY 2016 01:25AM EST | DOI: 10.1111/dom.12685


    1. A missense variant in GLP1R gene is associated with the glycemic response to treatment with gliptins

      Martin Javorský, Ivana Gotthardová, Lucia Klimčáková, Milan Kvapil, Jozef Židzik, Zbynek Schroner, Pavlína Doubravová, Igor Gaľa, Ingrid Dravecká and Ivan Tkáč

      Accepted manuscript online: 10 MAY 2016 01:20AM EST | DOI: 10.1111/dom.12682

    2. Effects of Obeticholic Acid on Lipoprotein Metabolism in Healthy Volunteers

      Richard Pencek, Tonya Marmon, Jonathan D. Roth, Alexander Liberman, Roya Hooshmand-Rad and Mark Young

      Accepted manuscript online: 25 APR 2016 12:35AM EST | DOI: 10.1111/dom.12681


    1. Exenatide decreases Liver fat content and Epicardial Adipose Tissue in Patients with obesity and Type 2 Diabetes: A prospective randomised clinical trial using Magnetic Resonance Imaging and Spectroscopy

      A. Dutour, I. Abdesselam, P. Ancel, F. Kober, G. Mrad, P. Darmon, O. Ronsin, V. Pradel, N. Lesavre, J.C. Martin, A. Jacquier, Y. Lefur, M. Bernard and B. Gaborit

      Accepted manuscript online: 23 APR 2016 01:25AM EST | DOI: 10.1111/dom.12680


    1. Gastrointestinal safety across the albiglutide development programme

      Lawrence A. Leiter, Jason M. Mallory, Timothy H. Wilson and Rickey R. Reinhardt

      Accepted manuscript online: 21 APR 2016 06:35AM EST | DOI: 10.1111/dom.12679


  1. 1 - 17